Home Newsfeeds Jefferies Downgrades SAP to Underperform

Jefferies Downgrades SAP to Underperform

Jefferies analyst Charles Brennan downgrades SAP (NYSE:SAP) from Buy to Underperform.

byBenzinga Newsdesk

November 18, 2022

1 minute read

Jefferies analyst Charles Brennan downgrades SAP (NYSE:SAP) from Buy to Underperform.

Why This UnitedHealth Analyst Sees Upside Ahead Following Q2 Earnings

By Wayne Duggan

July 15, 5:19 PM

Shares of UnitedHealth Group Inc (NYSE: UNH) rallied 5.38% on Friday after the health insurer reported a second-quarter earnings beat and hiked its full-year guidance.

UNH

Deutsche Bank Maintains Buy on Celanese, Raises Price Target to $135

By Benzinga Newsdesk

February 27, 10:49 AM

Deutsche Bank analyst David Begleiter maintains Celanese (NYSE:CE) with a Buy and raises the price target from $105 to $135.

Incannex Receives HREC Approval For Phase 2 Clinical Trial Assessing IHL-675A For Use In Treatment Of Pain And Function In Rheumatoid Arthritis

By Happy Mohamed

July 13, 8:15 AM

Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain and

IXHL

Daiwa Capital Initiates Coverage On SolarEdge Technologies with Neutral Rating, Announces Price Target of $325

By Benzinga Newsdesk

December 23, 9:29 AM

Daiwa Capital analyst Jonathan Kees initiates coverage on SolarEdge Technologies (NASDAQ:SEDG) with a Neutral rating and announces Price Target of $325.

SEDG

Jefferies Downgrades SAP to Underperform

Related Posts

Why This UnitedHealth Analyst Sees Upside Ahead Following Q2 Earnings

Deutsche Bank Maintains Buy on Celanese, Raises Price Target to $135

Incannex Receives HREC Approval For Phase 2 Clinical Trial Assessing IHL-675A For Use In Treatment Of Pain And Function In Rheumatoid Arthritis

Daiwa Capital Initiates Coverage On SolarEdge Technologies with Neutral Rating, Announces Price Target of $325